Cytokine Market Report by Cytokine Type, Therapeutic Application, End User, and Region 2024-2032
세계의 사이토카인 시장 규모는 2023년 896억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 1,633억 달러에 이를 전망이며, 예측 기간 동안 6.76%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
사이토카인은 면역계 및 혈액 세포의 증식 및 활성을 조절하기 위해 특정 세포로부터 방출되는 단백질, 펩티드 및 당단백질의 군을 말합니다. 고친화성 피코몰 농도이기 때문에 면역, 염증, 조혈을 조절할 수 있습니다. 일반적으로 화학 요법의 부작용 예방 및 관리, 암 치료에 도움이 피하 또는 근육과 정맥에 주사됩니다. 또, 이상세포를 사멸시켜, 정상세포를 장생시키는 시그널을 보내는 것으로, 항암 작용을 높입니다. 현재는 다양한 유형의 세포의 증식과 분화, 생체외 배양, 기타 치료 어프로치 등, 세포 치료나 유전자 치료에 널리 채용되고 있습니다.
사이토카인 시장 동향 :
코로나바이러스 감염(COVID-19)은 비말을 통해 감염되어 염증성 사이토카인의 과잉 생산을 유도하여 급성 호흡 곤란 증후군(ARDS)의 악화와 조직 손상을 유발합니다. 조직 손상은 다장기 부전과 사망으로 이어질 수 있으므로 환자를 관리하고 생존율을 높이고 사망률을 줄이기 위해 사이토카인을 표적으로하는 솔루션에 대한 수요가 증가하고 있습니다. 이와는 별도로 암 유병률 증가와 수술 후 통증과 합병증이 적고 회복이 빠른 저침습 수술(MIS)에 대한 수요 증가가 시장 성장에 기여하고 있습니다. 게다가 사이토카인은 건강이나 질환의 진단약, 예후 예측약, 치료, 바이오마커로서 기능하기 때문에 면역 세포의 분화, 염증, 혈관신생, 종양 형성, 신경 생물학, 바이러스 병원체 등 다양한 기능으로 지지 를 모으고 있습니다. 이 외에도 아토피 성 피부염(AD) 환자 수 증가는 심한 가려움증이있는 재발성 만성 염증성 피부 질환이며 AD의 병인에서 새로운 사이토카인에 대한 수요와 개선 된 치료 표적 개발을 촉진하고 있습니다.
이 보고서에서 다루는 주요 질문
- 세계의 사이토카인 시장은 지금까지 어떻게 추이해 왔는가?
- COVID-19는 세계의 사이토카인 시장에 어떤 영향을 미치는가?
- 주요 지역 시장은?
- 사이토카인 유형별 시장 분석은?
- 치료 용도별 시장 분석은?
- 최종 사용자별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 과제는?
- 세계의 사이토카인 시장의 구조와 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 사이토카인 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석: 사이토카인 유형별
- 종양 괴사 인자-TNF
- 인터루킨-II
- 인터페론-IFN
- 상피 성장 인자(EGF)
- 기타
제7장 시장 분석: 치료용도별
제8장 시장 분석 : 최종사용자별
- 제약,바이오테크놀러지 기업
- 계약 연구 기관
- 학술연구기관
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- AbbVie Inc.
- Abcam plc
- Amgen Inc.
- Applied Biological Materials Inc.(abm)
- Bio-Techne Corporation
- F. Hoffmann-La Roche AG
- GenScript Biotech Corporation
- Randox Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- UCB SA
BJH
The global cytokine market size reached US$ 89.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 163.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.76% during 2024-2032.
A cytokine refers to a group of proteins, peptides, or glycoproteins released by specific cells to control the growth and activity of the immune system and blood cells. It can regulate immunity, inflammation, and hematopoiesis on account of its high-affinity picomolar concentrations. It is usually injected under the skin or into muscles or veins to help prevent or manage chemotherapy side effects and treat cancer. It also boosts anti-cancer activities by sending signals that make abnormal cells die and normal cells live longer. Presently, it is gaining widespread adoption in cell and gene therapy for the expansion and differentiation of various cell types, ex vivo cultures, and other therapeutic approaches.
Cytokine Market Trends:
The coronavirus disease (COVID-19) is transmitted via droplets that can induce the excessive production of proinflammatory cytokines and lead to acute respiratory distress syndrome (ARDS) aggravation and tissue damage. As tissue damage can result in multi-organ failure and death, there is a rise in the demand for solutions that target cytokines to manage patients, improve survival rates, and reduce mortality. Apart from this, the increasing prevalence of cancer, in confluence with the escalating demand for minimally invasive surgeries (MIS) that provide less post-operative pain and complications and faster recovery time, is contributing to the market growth. Moreover, as cytokines act as diagnostic, prognostic, and therapeutic agents and biomarkers for health and diseases, they are gaining traction in diverse functions, including immune cell differentiation, inflammation, angiogenesis, tumorigenesis, neurobiology, and viral pathogenesis. Besides this, the rising cases of atopic dermatitis (AD), a recurrent, chronic, and inflammatory skin disease that processes with severe itchiness, is driving the demand for new cytokines in the pathogenesis of AD and developing improved therapeutic targets.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cytokine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cytokine type, therapeutic application and end user.
Breakup by Cytokine Type:
Tumor Necrosis Factor-TNF
Interleukins-Il
Interferons-IFN
Epidermal Growth Factor-EGF
Others
Breakup by Therapeutic Application:
Cancer
Asthma and Airway Inflammation
Arthritis
Others
Breakup by End User:
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Abcam plc, Amgen Inc., Applied Biological Materials Inc. (abm), Bio-Techne Corporation, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, Randox Laboratories Ltd., Thermo Fisher Scientific Inc. and UCB S.A.
Key Questions Answered in This Report:
- How has the global cytokine market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global cytokine market?
- What are the key regional markets?
- What is the breakup of the market based on the cytokine type?
- What is the breakup of the market based on the therapeutic application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cytokine market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cytokine Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Cytokine Type
- 6.1 Tumor Necrosis Factor-TNF
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Interleukins-Il
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Interferons-IFN
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Epidermal Growth Factor-EGF
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Therapeutic Application
- 7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Asthma and Airway Inflammation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Arthritis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End User
- 8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Contract Research Organizations
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Academic and Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Abcam plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Amgen Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 Applied Biological Materials Inc. (abm)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Bio-Techne Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 F. Hoffmann-La Roche AG
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 GenScript Biotech Corporation
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Randox Laboratories Ltd.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Thermo Fisher Scientific Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 UCB S.A.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
